ACADIA Pharmaceuticals (ACAD) to Release Quarterly Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) will likely be releasing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.13 per share and revenue of $292.5370 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals Trading Up 4.2%

Shares of NASDAQ ACAD opened at $22.95 on Wednesday. ACADIA Pharmaceuticals has a twelve month low of $13.40 and a twelve month high of $28.35. The firm has a 50-day moving average of $25.93 and a two-hundred day moving average of $24.44. The company has a market capitalization of $3.88 billion, a price-to-earnings ratio of 14.81, a PEG ratio of 7.73 and a beta of 0.66.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the transaction, the executive vice president owned 7,609 shares in the company, valued at $177,898.42. This represents a 47.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACAD. Vise Technologies Inc. lifted its stake in shares of ACADIA Pharmaceuticals by 4.0% in the 3rd quarter. Vise Technologies Inc. now owns 15,367 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 585 shares during the last quarter. FORA Capital LLC bought a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at approximately $297,000. Tower Research Capital LLC TRC lifted its stake in shares of ACADIA Pharmaceuticals by 250.6% in the second quarter. Tower Research Capital LLC TRC now owns 15,629 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 11,171 shares during the last quarter. Cetera Investment Advisers lifted its position in ACADIA Pharmaceuticals by 7.9% during the 2nd quarter. Cetera Investment Advisers now owns 12,763 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 931 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth about $220,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

ACAD has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 3rd. Oppenheimer reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Friday, February 6th. Piper Sandler set a $37.00 target price on ACADIA Pharmaceuticals in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday, December 29th. Finally, Stifel Nicolaus set a $37.00 price target on ACADIA Pharmaceuticals in a research report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $30.95.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.